Emergent BioSolutions Presents Efficacy Data on ES210; a Bispecific ADAPTIR
Molecule for Treating Autoimmune Diseases
ROCKVILLE, Md. -- April 11, 2013
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has presented
data on ES210, one of its bispecific ADAPTIR^TM (Modular Protein Technology)
molecules, that is targeting autoimmune disease at Keystone Symposia’s
Advances in the Knowledge and Treatment of Autoimmunity in Whistler, British
The ES210 molecule was engineered using Emergent’s ADAPTIR technology platform
and contains binding sites specific for CD86 coupled to a monomeric form of
IL-10 known to confer immunosuppressive activity.
The poster, entitled “A Bispecific ADAPTIR™ Molecule That Targets CD86 and
Delivers IL-10 Inhibits Antigen Presenting Cells and Has Potential as a
Therapeutic Treatment of Autoimmune Disease,” presented pre-clinical data
showing that ES210 displays high levels of in vitro and in vivo potency in
blocking T-cell proliferation in human mixed lymphocyte reactions and in a
humanized graft-versus-host disease model. Dendritic cells play a central role
in the generation and regulation of immunity; therefore, targeting dendritic
cell function represents a therapeutic opportunity to suppress
immunopathological processes in autoimmune disease.
“Emergent is investigating an ADAPTIR molecule that targets and blocks the
co-stimulatory receptor CD86, while delivering the immunosuppressive cytokine
IL-10 to CD86-expressing antigen presenting cells,” said Jane Gross, Ph.D.,
vice president of applied research at Emergent BioSolutions. “We are pleased
to present the study results, which show the ADAPTIR molecule as having
potential applications in the treatment of transplant rejection as well as
autoimmune and inflammatory diseases such as Crohn’s disease, ulcerative
colitis, and rheumatoid arthritis.”
About the ADAPTIR™ Platform
ADAPTIR bispecific proteins are modular, single chain polypeptides that
comprise two separate binding domains (VL and VH), a hinge segment, and an
effector domain (huFc). They have a differentiated structure from monoclonal
antibodies and can generate a unique signaling response. In addition, ADAPTIR
proteins may mediate complement dependent cytotoxicity and Fc dependent
cytotoxicity, similar to monoclonal antibodies.
ADAPTIR is the new trademark for Emergent BioSolutions Inc.’s modular protein
technologies that were previously identified using the SCORPION^TM
(multispecific protein therapeutic) and SMIP^TM (monospecific protein
therapeutic) trademarks. ADAPTIR and any and all Emergent BioSolutions Inc.
brand, product, service and feature names, logos and slogans are trademarks or
registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the
United States or other countries. All rights reserved.
About Emergent BioSolutions
Emergent BioSolutions is a specialty pharmaceutical company seeking to protect
and enhance life by offering specialized products to healthcare providers and
governments to address medical needs and emerging health threats. Additional
information may be found at www.emergentbiosolutions.com. Follow us on
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Any statements, other
than statements of historical fact, are forward-looking statements.
Forward-looking statements in this press release include statements about the
potential and therapeutic opportunity of the ADAPTIR molecule. These
forward-looking statements are based on our current intentions, beliefs and
expectations regarding future events. We cannot guarantee that any
forward-looking statement will be accurate. Investors should realize that if
underlying assumptions prove inaccurate or unknown risks or uncertainties
materialize, actual results could differ materially from our expectations.
Investors are, therefore, cautioned not to place undue reliance on any
forward-looking statement. Any forward-looking statement speaks only as of the
date of this press release, and, except as required by law, we do not
undertake to update any forward-looking statement to reflect new information,
events or circumstances.
There are a number of important factors that could cause the company’s actual
results to differ materially from those indicated by such forward-looking
statements, including the success of our ongoing and planned preclinical
studies and clinical trials; the rate and degree of market acceptance and
clinical utility of our products; the timing of and our ability to obtain and
maintain regulatory approvals for our product candidates; and our
commercialization, marketing and manufacturing capabilities and strategy. The
foregoing sets forth many, but not all, of the factors that could cause actual
results to differ from our expectations in any forward-looking statement.
Investors should consider this cautionary statement, as well as the risk
factors identified in our periodic reports filed with the SEC, when evaluating
our forward-looking statements.
Robert G. Burrows, 301-795-1877
Vice President, Investor Relations
Tracey Schmitt, 301-795-1800
Vice President, Corporate Communications
Press spacebar to pause and continue. Press esc to stop.